Abstract
A series of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles, 7a–c, 11a–h, and 16a–h has been synthesised and evaluated for their ALK5 inhibitory activity in an enzyme assay and in a cell-based luciferase reporter assay. Incorporation of a quinoxalin-6-yl moiety and a methylene linker at the 4- and 2-position of the imidazole ring, respectively, and a m-CONH2 substituent in the phenyl ring generated a highly potent and selective ALK5 inhibitor 11e. Docking model of ALK5 in complex with 11e showed that it fitted well in the ATP-binding pocket with favourable interactions.
Original language | English |
---|---|
Pages (from-to) | 702-712 |
Number of pages | 11 |
Journal | Journal of Enzyme Inhibition and Medicinal Chemistry |
Volume | 35 |
Issue number | 1 |
DOIs | |
State | Published - 1 Jan 2020 |
Bibliographical note
Funding Information:This work was supported by the Ministry of Commerce, Industry and Energy, Korea under grant [numbers M1-0310-43-0001 and M1-0310-43-0002].
Publisher Copyright:
© 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Keywords
- 2,4-Disubstituted-5-(6-alkylpyridin-2-yl)-1H-imidazoles
- ALK5 inhibition
- cancer immunotherapeutic agent
- docking